-
Signature
-
/s/ Christian Kuhlen, attorney-in-fact
-
Issuer symbol
-
ORIC
-
Transactions as of
-
16 Jan 2026
-
Net transactions value
-
-$80,431
-
Form type
-
4
-
Filing time
-
20 Jan 2026, 19:19:28 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Heyman Richard A. |
Director |
C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO |
/s/ Christian Kuhlen, attorney-in-fact |
20 Jan 2026 |
0001584759 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ORIC |
Common Stock |
Sale |
$42,016 |
-3,500 |
-7.7% |
$12.00 |
41,800 |
16 Jan 2026 |
Direct |
F1, F2 |
| transaction |
ORIC |
Common Stock |
Sale |
$38,415 |
-3,200 |
-1.5% |
$12.00 |
213,072 |
16 Jan 2026 |
See footnote |
F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: